Sio Gene Therapies (NASDAQ:SIOX) Vs. Organigram (NASDAQ:OGI) Head-To-Head Review
Sio Gene Therapies (NASDAQ:SIOX) Vs. Organigram (NASDAQ:OGI) Head-To-Head Review
Sio Gene Therapies (NASDAQ:SIOX – Get Rating) and Organigram (NASDAQ:OGI – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.
Sio 基因療法（NASDAQ：SIOX-獲得評級）和有機圖（NASDAQ：OGI-獲取評級）都是小型股醫療公司，但哪些是優越的股票？我們將根據兩家公司的收益，機構所有權，風險，估值，股息，盈利能力和分析師建議的實力進行比較。
Valuation and Earnings
估值及收益
This table compares Sio Gene Therapies and Organigram's top-line revenue, earnings per share (EPS) and valuation.
該表比較了 Sio 基因療法和 Organigram 的頂級收入，每股收益（EPS）和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sio Gene Therapies | N/A | N/A | -$71.89 million | N/A | N/A |
| Organigram | $111.27 million | 1.81 | -$11.23 million | ($0.03) | -21.33 |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股盈利 | 市盈比率 | |
| 基因療法 | N/A | N/A | -7,189 萬美元 | N/A | N/A |
| 組織圖 | 一億一千一百二十七萬元 | 1.81 | -一千一百二十三萬元 | (0.03 美元) | -21.33 |
Organigram has higher revenue and earnings than Sio Gene Therapies.
有機圖比 Sio 基因療法具有更高的收入和收入。
Analyst Ratings
分析師評級
This is a breakdown of recent recommendations and price targets for Sio Gene Therapies and Organigram, as provided by MarketBeat.
這是 MarketBeat 提供的最近 Sio 基因療法和有機圖的建議和價格目標的細分。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sio Gene Therapies | 1 | 1 | 0 | 0 | 1.50 |
| Organigram | 0 | 0 | 2 | 0 | 3.00 |
| 銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
| 基因療法 | 1 | 1 | 0 | 0 | 1.50 |
| 組織圖 | 0 | 0 | 2 | 0 | 3.00 |
Sio Gene Therapies presently has a consensus target price of $0.80, indicating a potential upside of 98.02%. Organigram has a consensus target price of $1.67, indicating a potential upside of 160.42%. Given Organigram's stronger consensus rating and higher possible upside, analysts plainly believe Organigram is more favorable than Sio Gene Therapies.
Sio 基因療法目前的共識目標價格為 0.80 美元，表明潛在的上行空間為 98.02％。有機圖的共識目標價為 1.67 美元，表明潛在的上行空間為 160.42％。鑑於 Organigram 更強的共識評級和更高的可能上行空間，分析師清楚地認為 Organigram 比 Sio 基因療法更有利。
Profitability
盈利
This table compares Sio Gene Therapies and Organigram's net margins, return on equity and return on assets.
該表比較了 Sio 基因療法和 Organigram 的淨利潤率，股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Sio Gene Therapies | N/A | -55.94% | -48.33% |
| Organigram | -4.97% | -6.00% | -5.30% |
| 淨利潤 | 權益回報率 | 資產回報率 | |
| 基因療法 | N/A | -55.94% | -48.33% |
| 組織圖 | -4.97% | -6.00% | -5.30% |
Insider and Institutional Ownership
內幕和機構所有權
11.0% of Organigram shares are owned by institutional investors. 3.4% of Sio Gene Therapies shares are owned by company insiders. Comparatively, 0.1% of Organigram shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
有機構投資者擁有 11.0％ 的股份。Sio Gene 療法股份的 3.4％ 由公司內部人士擁有。相比之下，0.1％ 的 Organigram 股票由公司內部人士擁有。強大的機構所有權表明，捐贈基金，大型資金經理和對沖基金認為公司長期的表現將優於市場。
Summary
摘要
Organigram beats Sio Gene Therapies on 8 of the 10 factors compared between the two stocks.
與兩隻股票相比，有機圖在 8 個因素中的 10 個因素中擊敗了 Sio 基因療法。
About Sio Gene Therapies
關於 Sio 基因療法
(Get Rating)
(取得評分)
Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focuses on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis, such as Tay-Sachs disease and Sandhoff disease. The company was founded on October 31, 2014 and is headquartered in New York, NY.
Sio Gene Therapies, Inc. 是一家臨床階段生物製藥公司，從事神經系統疾病基因療法的收購、開發和商業化。其產品線主要集中在帕金森病、GM1 神經性傳染病和 GM2 神經性傳染病，例如泰-薩克斯病和沙霍夫病。該公司成立於 2014 年 10 月 31 日，總部位於紐約州紐約。
About Organigram
關於有機圖
(Get Rating)
(取得評分)
OrganiGram Holdings, Inc. engages in the production and sale of medical marijuana. It focuses on producing cannabis for patients and adult recreational consumers. The firm's brands include Adult Recreational and Medical. The company was founded on July 5, 2010 and is headquartered in Moncton, Canada.
有機金控股有限公司從事醫用大麻的生產和銷售。它專注於為患者和成人娛樂消費者生產大麻。該公司的品牌包括成人娛樂和醫療。該公司成立於 2010 年 7 月 5 日，總部位於加拿大蒙克頓。
Receive News & Ratings for Sio Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sio Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收 Sio 基因療法的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Sio 基因療法及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。